Fifty Years On: GWAS Confirms the Role of a Rare Variant in Lung Disease

PLoS Genetics

Volumn 9, Issue 8, 2013, Pages

  Turner, Alice M ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ACTIVITY; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG DISEASE; LUNG FUNCTION; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SERPINA1 GENE;

ALPHA 1-ANTITRYPSIN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84884657684     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003768     Document Type: Article

References (12)

1. Thun GA, Imboden M, Ferrarotti I, Kumar A, Obeidat M, et al. (2013) Causal and synthetic associations of variants in the serpina gene cluster with alpha1-antitrypsin serum levels. PLoS Genet 9 (8) (): e1003585 doi:10.1371/journal.pgen.1003585.
2. Obeidat M, Wain LV, Shrine N, Kalsheker N, Artigas MS, et al. (2011) A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample. PLoS One 6: e19382.
3. Sorheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, et al. (2010) alpha(1)-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 138: 1125-1132.
4. Laurell CB, Eriksson S, (1963) The electrophoretic alpha 1 globulin pattern of serum in alpha 1 antitrypsin deficiency. Scand J Clin Lab Invest 15: 132-140.
5. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, et al. (1982) Structure and variation of human alpha 1-antitrypsin. Nature 298: 329-334.
6. Luisetti M, Seersholm N, (2004) Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 59: 164-169.
7. Global Initiative for Obstructive Lung Disease.Available: http://www.goldcopd.org. Accessed June 2013.
8. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, et al. (2009) A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 5: e1000421.
9. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, et al. (2009) MMP12, lung function, and COPD in high-risk populations. N Engl J Med 361: 2599-2608.
10. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.
11. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ, (2009) Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 6: 177-184.
12. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, et al. (2010) Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 11: 136.